Anthony Troitino, MD
Pulmonary Disease · Oklahoma City, OKNPI 1689966103
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,735 and has fallen 98.1% since, to $33 in 2025.
Across 255 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$938
- Regeneron Healthcare Solutions, Inc.$451
- Boehringer Ingelheim$421
- Teva Pharmaceuticals USA, Inc.$170
- Johnson & Johnson$135
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,304100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 69 | $1,005 |
| AstraZeneca(2 entities) | 47 | $938 |
| Regeneron Healthcare Solutions, Inc. | 33 | $451 |
| Boehringer Ingelheim | 22 | $421 |
| Teva Pharmaceuticals USA, Inc. | 9 | $170 |
| Johnson & Johnson | 9 | $135 |
| Genentech USA, Inc. | 8 | $131 |
| Sanofi | 6 | $127 |
| Actelion Pharmaceuticals US, Inc. | 4 | $111 |
| Advanced Respiratory, Inc | 5 | $107 |
| Novartis | 5 | $89 |
| Philips North America LLC | 5 | $82 |
| Electromed, Inc. | 7 | $82 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| Jazz Pharmaceuticals Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Pfizer | 3 | $41 |
| Shire North American Group Inc | 2 | $41 |
| Mylan Specialty L.p. | 3 | $40 |
| Abiomed | 1 | $33 |
| Merck | 2 | $27 |
| United Therapeutics Corporation | 1 | $23 |
| Fisher & Paykel Healthcare Inc | 1 | $20 |
| Pulmonx Corporation | 1 | $18 |
| Insmed, Inc. | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$221
- FASENRA$221
- BREZTRI AEROSPHERE$113
How this compares
$4,305 in reported general payments places this provider in the 65th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.